Daridorexant: exploring its role in the treatment of insomnia disorder

Consistent nightly treatment with daridorexant showed significant and clinically meaningful improvements in both sleep and daytime functioning at the 50 mg dose. In clinical trials, daridorexant demonstrated efficacy across objective and patient-reported sleep measures in a broad adult population, including older adults, and efficacy was maintained for up to 1 year. Reduced wakefulness throughout the entire night with daridorexant was associated with improvement in daytime functioning. Head-to-head comparisons with standard insomnia hypnotics are limited to a Phase 2 dose-finding study. Its favorable safety profile makes daridorexant appropriate for many patients, including older adults.